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Elevated Baseline Serum Fibrinogen: Effect on 2-Year Major Adverse
Cardiovascular Events Following Percutaneous Coronary Intervention
Lawrence Ang, MD; Omid Behnamfar, MD; Samhita Palakodeti; Felice Lin, MD; Ali Pourdjabbar, MD; Mitul P. Patel, MD;
Ryan R. Reeves, MD; Ehtisham Mahmud, MD
Background-—Elevated fibrinogen is associated with short-term major adverse cardiovascular events (MACE) after percutaneous
coronary intervention, but the relation with late MACE is unknown.
Methods and Results-—Baseline demographics and 2-year MACE were recorded among subjects undergoing nonemergent
percutaneous coronary intervention. A total of 332 subjects (66.619.5 years, 69.9% male, 25.3% acute coronary syndrome) were
enrolled. Two-year MACE (periprocedural myocardial infarction 9.0%, rehospitalization 6.3%, revascularization 12.7%, non–
periprocedural myocardial infarction 4.5%, stent thrombosis 0.9%, stroke 1.8%, and death 0.6%) were associated with higher
fibrinogen (352.8123.4 mg/dL versus 301.6110.8 mg/dL; P<0.001), longer total stent length (40.125.3 mm versus
32.119.3 mm; P=0.004), acute coronary syndrome indication (38.7% versus 17.8%; P<0.001), number of bare-metal stents
(0.51.1 versus 0.20.5; P=0.002), and stent diameter ≤2.5 mm (55.8% versus 38.4%, P=0.003). No relation between platelet
reactivity and 2-year MACE was observed. Fibrinogen ≥280 mg/dL (odds ratio [OR] 3.0, confidence interval [CI], 1.6–5.4,
P<0.001), total stent length ≥32 mm (OR 2.2, CI, 1.3–3.8, P<0.001), acute coronary syndrome indication (OR 4.1, CI, 2.3–7.5,
P<0.001), any bare-metal stents (OR 3.2, CI, 1.6–6.1, P<0.001), and stent diameter ≤2.5 mm (OR 2.0, CI, 1.2–3.5, P=0.010) were
independently associated with 2-year MACE. Following a landmark analysis excluding periprocedural myocardial infarction,
fibrinogen ≥280 mg/dL remained strongly associated with 2-year MACE (37.0% versus 17.4%, log-rank P<0.001).
Conclusions-—Elevated baseline fibrinogen level is associated with 2-year MACE after percutaneous coronary intervention. Acute
coronary syndrome indication for percutaneous coronary intervention, total stent length implanted, and use of bare-metal stents or
smaller-diameter stents are also independently associated with 2-year MACE, while measures of on-thienopyridine platelet
reactivity are not. ( J Am Heart Assoc. 2017;6:e006580. DOI: 10.1161/JAHA.117.006580.)
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E levated serum fibrinogen level is associated with majoradverse cardiovascular events (MACE) after percuta-
neous coronary intervention (PCI) for patients with both
elective and urgent indications.1–3 Aside from being an acute
phase reactant of inflammation, fibrinogen has crucial mech-
anistic roles in platelet crosslinking, platelet aggregation, and
thrombus formation.4 Previously, it has been identified as a
risk factor for both short- and long-term adverse cardiovas-
cular events.5–14 More recently, elevated baseline fibrinogen
level has been reported to be associated with higher on-
thienopyridine platelet reactivity, periprocedural myocardial
infarction (MI), and combined MACE within 12 months of the
index PCI.1–3,15 The present study was performed to deter-
mine whether a longer term adverse relationship between
baseline serum fibrinogen level, on-thienopyridine platelet
reactivity, and ischemic cardiovascular events exists in
patients undergoing PCI for both elective or acute coronary
syndrome (ACS) indications.
Methods
Patient Selection
The study was approved by the Institutional Review Board of the
University of California, San Diego and the requirement for
informed written consent was waived. Data from patients with
coronary artery disease who underwent successful PCI with
stentingorballoonangioplastyaloneandmeasurementofserum
fibrinogen within 24 hours of PCI were retrospectively gathered
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from a PCI database and electronic medical record. All subjects
hadbeenpretreatedwithathienopyridine for≥7 daysbeforePCI
or received a loading dose of clopidogrel 600 mg or prasugrel
60 mg at least 2 hours before PCI. Those with ST-segment–
elevationMIwithin72 hoursbefore recruitment,age<18 years,
or use of intravenous glycoprotein IIb/IIIa inhibitor within
30 days before index PCI were excluded.
Measurements
Baseline subject characteristics, history of cardiovascular
disease and comorbidities, serum laboratory measurements,
procedural details, postprocedure cardiac marker levels, and
2-year MACE were recorded. Baseline serum laboratory
measurements included complete blood count, creatinine,
complete lipid panel, C-reactive protein, fibrinogen, and
cardiac markers of ischemic injury (creatine kinase–myocar-
dial band, troponin I and/or troponin T) and were performed
at the University of California, San Diego Medical Center.
Cardiac markers of ischemic injury were measured every 6 to
8 hours following PCI until hospital discharge or up to
24 hours. Platelet function testing was performed during PCI
using the VerifyNow P2Y12 assay (Accumetrics, San Diego,
CA) with on-treatment platelet reactivity reported as “result”
P2Y12 reaction units (PRU) and maximal platelet activation
using high-concentration thrombin receptor-activating protein
reported as “base” PRU. Platelet inhibition or percent change
in result PRU from baseline (calculated as [1(result PRU)/
(base PRU)]9100%)16 was also reported as available. MACE
included periprocedural MI (<24 hours after PCI: creatine
kinase–myocardial band elevation at least 3-fold greater than
the 99% upper limit of normal with normal baseline, or >20%
rise from stable elevated baseline),17 nonperiprocedural MI
(>24 hours after PCI) with or without concurrent ST-segment
elevation, rehospitalization for a suspected ACS, unplanned
repeat revascularization, definite stent thrombosis, transient
ischemic attack, ischemic or hemorrhagic stroke, or any
death.
Statistical Analysis
The study was performed using a nested case–control design
and powered to detect a 52 mg/dL difference in mean
fibrinogen level between outcome groups (361 mg/dL versus
309 mg/dL, overall SD 109 mg/dL) at 6 months, using a
0.05 and power 0.8. This analysis revealed that at least 69
outcome events were needed.1 Collection of study data from
eligible subjects was continued until 69 MACE events were
recorded at 6 months, then enrollees had both 6-month and
2-year MACE events identified. Results from the combined 2-
year MACE are reported.
Variables of interest were compared across MACE out-
come groups using Student t tests or v2 analysis as
appropriate. Significant continuous variables underwent
receiver-operator characteristic curve analysis to determine
cutoff values with greatest sum sensitivity and specificity in
predicting events. Factors having significant univariate rela-
tionships with MACE (P<0.05) were entered together into a
binary logistic multiple regression model. Significant relation-
ships and Kaplan–Meier event-free survival are reported.
Interaction testing between significant variables was also
performed.
Results
A total of 332 subjects were enrolled (mean age
66.619.5 years, 69.9% men). The study population had a
high prevalence of risk factors for cardiovascular disease
(42.9% diabetes mellitus, 90.6% hypertension, 87.2% hyper-
lipidemia), and prior coronary revascularization (61.4% PCI,
17.0% coronary artery bypass grafting) (Table 1). The majority
of subjects underwent elective PCI while a quarter of the
study population had an urgent indication for index PCI (12.3%
non–ST-segment–elevation MI, 13.0% unstable angina). An
average of 1.40.7 lesions were treated using 1.71.1
stents (83.4% using drug-eluting stents, 16.3% using at least 1
Clinical Perspective
What Is New?
• This study uniquely identifies baseline serum fibrinogen as a
significant, independent risk factor for late major adverse
cardiovascular events after percutaneous coronary inter-
vention (PCI).
• The association between baseline fibrinogen level and
cardiovascular events in the post-PCI context and extending
to 2-year follow-up after index PCI are novel study
contributions.
• Additional analyses uniquely highlight the independent
association between serum fibrinogen and 1) objective,
clinically relevant ischemic cardiovascular events, and 2)
nonacute events occurring >24 hours after PCI.
What Are the Clinical Implications?
• Incorporation of fibrinogen level measurement may
strengthen the ability of ischemic risk prediction strategies
to identify individuals at higher risk of late major adverse
cardiovascular events occurring 12 to 24 months after PCI.
• Individuals with elevated fibrinogen could potentially benefit
from prolonged dual-antiplatelet therapy extended beyond
12 months after index PCI or potentially oral direct
thrombin inhibitors.
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bare-metal stent [BMS]) in each patient, though a small
minority underwent balloon angioplasty alone (4.8%).
Two-year MACE after PCI occurred in 123 subjects (total
events 35.8%: periprocedural MI alone 9.0%, rehospitalization
for suspected ACS 6.3%, urgent revascularization 12.7%, non–
ST-segment–elevation MI or ST-segment–elevation MI 4.5%,
definite stent thrombosis 0.9%, transient ischemic attack or
stroke 1.8%, all death 0.6%). Baseline subject characteristics,
cardiac risk factors, comorbidities, and pharmacotherapy were
comparedbetween thosewithandwithoutMACE (Table 2).Serum
fibrinogen level (352.8123.4 mg/dL versus 301.6110.8 mg/
dL, P<0.001) and white blood cell count (7.72.8 103 cells/dL
versus 7.12.5 103 cells/dL, P=0.024) were higher in thosewith
MACE, but other markers of systemic inflammation were similar
betweenoutcomegroups(C-reactiveprotein:1.22.7 mg/Lversus
0.81.5 mg/L, P=0.225; platelet count: 228.389.8 103 cells/
dL versus 215.465.5 103 cells/dL, P=0.172). Platelet reactivity
measurements were similar between cohorts with and without
MACE(basePRU:330.058.7versus316.764.8,P=0.633; result
PRU: 146.330.0 versus 167.1102.7, P=0.282; platelet inhibi-
tion: 37.925.2% versus 37.126.4%, P=0.893; PRU>208: 42.9%
versus 30.6%, P=0.348; PRU >230: 28.6% versus 27.8%, P=0.949;
platelet inhibition<30%: 46.1% versus 45.7%, P=0.959). Those with
2-yearMACEmorecommonlyhadahistoryofcoronaryarterybypass
grafting (22.6% versus 13.9%, P=0.046), more often presented with
ACS (38.7% versus 17.8%, P<0.001), but not non–ST-segment–
elevationMI(16.0%versus10.3%,P=0.134),at indexPCI. Inaddition,
PCI in this cohort wasmore commonly performedwithin a coronary
artery bypassgraft (5.9%versus1.4%,P=0.039) andwasassociated
withgreater totalstentnumber (1.91.3versus1.60.9,P=0.017),
total stent length (TSL) (40.125.3 mm versus 32.119.3 mm,
P=0.004), total BMS number (0.51.1 versus 0.20.5; P=0.002),
and total number of stents ≤2.5-mm diameter (0.91.1 versus
0.50.8, P=0.002) during PCI (Table 3). Glycoprotein IIb/IIIa
inhibitor use was similar between outcome groups (17.8% versus
14.8%, P=0.470), while post-PCI use of prasugrel was low but more
common among those withMACE (7.6% versus 2.8%, P=0.046).
Receiver-operator characteristic curve analysis showed
fibrinogen level ≥280 mg/dL (area 0.613, P<0.001), TSL
≥32 mm (area 0.589, P=0.009), use of at least 1 BMS (area
0.578, P=0.018), use of at least 1 ≤2.5-mm diameter stent
(area 0.592, P=0.006), and white blood cell count
≥5.69103 cells/dL (area 0.585, P=0.011) to have maximum
sensitivity and specificity in predicting occurrence of 2-year
MACE.
Multiple variable testing was performed using significant
univariate factors (fibrinogen ≥280 mg/dL, white blood cell
count ≥5.69103 cells/dL, prior coronary artery bypass
grafting, ACS indication, bypass graft PCI, TSL ≥32 mm, at
least 1 BMS used, at least 1 ≤2.5-mm diameter stent used,
and post-PCI prasugrel use). Fibrinogen level ≥280 mg/dL
(P<0.001), ACS indication (P<0.001), TSL ≥32 mm
(P=0.005), use of a BMS (P=0.001), and use of a ≤2.5-mm
diameter stent (P=0.008) remained significantly associated
with occurrence of 2-year MACE, while other factors did not.
No interactions between these significant variables were
identified. Adjusted odds ratios (OR) for fibrinogen level
≥280 mg/dL (OR 3.0, confidence interval [CI], 1.6–5.4,
P<0.001), ACS indication (OR 4.1, CI, 2.3–7.5, P<0.001),
TSL ≥32 mm (OR 2.2, CI, 1.3–3.8, P=0.005), use of a BMS
(OR 3.2, CI, 1.6–6.1, P<0.001), and use of a ≤2.5-mm stent
(OR 2.1, CI, 1.2–3.5, P<0.001) are reported between these
independent factors (Figure 1).
A post hoc analysis comparing these 5 factors and 2-year
MACE excluding rehospitalization for ACS was performed,
which showed persistent relationships for fibrinogen level
≥280 mg/dL (P=0.004), ACS indication (P<0.001), TSL
≥32 mm (P<0.001), and use of a BMS (P=0.001). This
analysis was repeated excluding both rehospitalization for
ACS and revascularization (without an inciting MI) from 2-year
MACE, which demonstrated significant relationships between
fibrinogen level ≥280 mg/dL (P=0.018), ACS indication
(P=0.002), TSL ≥32 mm (P=0.002), and use of a BMS
(P=0.001) with unequivocal adverse events (non–ST-
segment–elevation MI /ST-segment–elevation MI, stent
thrombosis, stroke/transient ischemic attack, and all-cause
death).
Kaplan–Meier curve analysis showed increased 2-year
MACE among those with fibrinogen ≥280 mg/dL (42.6%
Table 1. Study Population Baseline Characteristics
MeanSD or %
Age, y 66.619.5
Male sex, % 69.9
Body mass index, kg/m2 28.65.9
Past MI, % 32.1
Past PCI, % 61.4
Past CABG, % 17.0
Hypertension, % 90.6
Hyperlipidemia, % 87.2
Family history of CVD, % 46.7
Diabetes mellitus, % 42.9
Smoking, % 14.4
LV ejection fraction, % 57.712.2
Acute coronary syndrome, % 25.3
NSTEMI, % 12.3
Unstable angina, % 13.0
CABG indicates coronary artery bypass grafting; CVD, cardiovascular disease; LV, left
ventricular; MI, myocardial infarction; NSTEMI, non–ST-segment–elevation myocardial
infarction; PCI, percutaneous coronary intervention.
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versus 22.0%, log-rank P<0.001) (Figure 2). More specifically,
fibrinogen ≥280 mg/dL was associated with increased MACE
among those undergoing PCI for either elective indications
(35.4% versus 17.9%, log-rank P=0.005) or for an ACS (62.7%
versus 36.0%, log-rank P=0.023) (Figure 3). A landmark
survival analysis at 24 hours (excluding periprocedural MI
Table 2. Clinical Characteristics Compared Between Subjects With and Without 2-Year MACE
No Events (n=209) MACE (n=123) P Value
Age, y 65.811.7 68.128.5 0.397
Male sex, % 71.4 67.2 0.431
BMI, kg/m2 29.06.0 28.05.7 0.141
Past PCI, % 59.4 65.0 0.325
Past CABG, % 13.9 22.6 0.046
Past MI, % 29.4 36.9 0.169
Diabetes mellitus, % 42.5 43.6 0.842
Hypertension, % 90.1 91.5 0.696
Hyperlipidemia, % 87.3 87.1 0.947
Family history, % 42.5 43.6 0.842
Smoking history, % 13.1 16.8 0.379
Medications
Aspirin, % 87.6 86.7 0.818
Clopidogrel, % 65.9 67.8 0.723
Prasugrel, % 0.5 1.7 0.291
Statin, % 79.4 77.7 0.715
b-Blocker, % 65.6 69.6 0.457
ACE inhibitor/ARB, % 61.7 61.6 0.984
Nitrates, % 33.3 29.7 0.512
Calcium channel blocker, % 22.1 28.6 0.199
Anticoagulation, % 7.2 8.1 0.772
Laboratory values
WBC, 103 cells/dL 7.12.5 7.72.8 0.024
Hemoglobin, g/dL 12.91.6 12.71.6 0.309
Platelet, 103 cells/dL 215.465.5 228.389.8 0.172
Creatinine, mg/dL 1.21.3 1.41.5 0.139
HbA1c, % 6.71.4 7.12.4 0.394
Total cholesterol, mg/dL 145.038.3 148.252.0 0.528
LDL, mg/dL 83.532.7 79.731.4 0.983
HDL, mg/dL 40.216.1 39.612.8 0.715
Triglyceride, mg/dL 120.082.3 149.7271.7 0.250
Fibrinogen, mg/dL 301.6110.8 352.8123.4 <0.001
C-reactive protein, mg/L 0.81.5 1.22.7 0.225
Platelet reactivity (VerifyNow P2Y12 assay)
Base PRU, PRU 316.764.8 330.058.7 0.633
Result PRU, PRU 167.1102.7 146.330.0 0.282
Platelet inhibition, % 37.126.4 37.925.2 0.893
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass grafting; HbA1c, hemoglobin A1c; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; MACE, major adverse cardiovascular events; MI, myocardial infarction; PCI, percutaneous coronary intervention; PRU, P2Y12 reaction unit; WBC,
white blood cell.
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occurring <24 hours after PCI) showed significantly greater 2-
year MACE in those with elevated fibrinogen (37.0% versus
18.3%, log-rank P<0.001) (Figure 4). The combined presence
of any of the identified risk factors above was associated with
a stepwise increase in MACE (0, 1, 2, 3, to 4 total risk factors:
8.3% versus 18.6% versus 31.2% versus 54.9% versus 84.6%
2-year MACE, log-rank P<0.001) (Figure 5).
Discussion
The current study demonstrates that higher baseline fibrino-
gen is an independent predictor of 2-year MACE after elective
or urgent PCI, and is driven by objective, clinically relevant
ischemic cardiovascular events, independent of periprocedu-
ral MI. Additionally, index PCI for an ACS, longer total
implanted stent length, use of BMS, and use of small-caliber
stents are also independent predictors of 2-year MACE, while
measures of platelet reactivity using the VerifyNow P2Y12
assay are not. Post hoc analyses using objective, clinically
relevant definitions of ischemic events as well as a 24-hour
landmark provide insight into the relation between baseline
fibrinogen level and post-PCI MACE beyond prior reports at 6
and 12 months of follow-up.
Kaplan–Meier survival curves, based on the fibrinogen
cutoff of 280 mg/dL, show early and persistent separation
during 2-year follow-up after index PCI. A 24-hour landmark
analysis demonstrates that this relation persists after exclud-
ing periprocedural MI. In fact, subjects with elevated baseline
fibrinogen (≥280 mg/dL) had higher incidence of subsequent
ACS hospitalization, revascularization, MI, definite stent
thrombosis, stroke, or death beyond 24 hours after PCI. This
relation between elevated fibrinogen and 2-year MACE also
persisted when limiting the analysis to only include acute MI,
stent thrombosis, stroke, and death in the 2-year end point
(excluding both ACS rehospitalization and revascularization
without an inciting MI). These findings highlight the potential
role for elevated baseline fibrinogen level to identify those at
higher risk of future ischemic events that are both of high
clinical relevance and occurring relatively late (12–24 months
after index PCI).
Table 3. Procedural Characteristics Compared Between Subjects With and Without 2-Year MACE
Control (n=209) MACE (n=123) P Value
PCI indication
Acute coronary syndrome, % 17.8 38.7 <0.001
NSTEMI, % 10.3 16.0 0.134
Unstable angina, % 7.5 22.7 <0.001
Procedural details
Total segments treated 1.30.6 1.50.8 0.096
Stents per procedure 1.60.9 1.91.3 0.017
Total drug-eluting stents 1.51.0 1.51.2 0.978
Total bare-metal stents 0.20.5 0.51.1 0.002
Total small-caliber stents (2.0–2.5 mm) 0.50.8 0.91.1 0.002
Total stent length, mm 32.119.3 40.125.3 0.004
Pre-PCI stenosis, % 83.39.2 84.110.2 0.527
Post-PCI stenosis, % 1.44.4 3.010.7 0.127
LAD lesion, % 53.1 52.9 0.985
Bypass graft lesion, % 1.4 5.9 0.039
Chronic total occlusion lesion, % 4.2 2.5 0.548
Bivalirudin, % 84.3 80.5 0.383
Unfractionated heparin, % 16.7 24.6 0.083
Glycoprotein IIb/IIIa inhibitor, % 14.8 17.8 0.470
Post-PCI thienopyridine
Clopidogrel, % 96.2 91.6 0.073
Prasugrel, % 2.8 7.6 0.046
LAD indicates left anterior descending artery; MACE, major adverse cardiovascular events; NSTEMI, non–ST-segment–elevation myocardial infarction; PCI, percutaneous coronary
intervention.
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The presence of other clinically relevant factors including
ACS presentation, greater total stent length, use of BMS, and
use of small-caliber stents were independently associated
with 2-year MACE and suggested roles for baseline disease
burden and procedural details on subsequent events regard-
less of fibrinogen level. In particular, the use of BMS may
represent the use of smallest-diameter stents (2.0 mm) or
presence of comorbidities warranting shorter dual antiplatelet
therapy duration. Total stent length difference between
groups was also clinically relevant, representing greater
underlying disease burden requiring multiple stents and more
complex PCI procedures in those with subsequent MACE. The
presence of multiple factors together with elevated fibrinogen
level was associated with the greatest 2-year risk of MACE.
An analysis of the GRAVITAS (Gauging Responsiveness With a
VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety)
Trial also identified multiple significant covariates, notably
ACS presentation and TSL, in predicting 6-month combined
death, MI, and stent thrombosis after PCI for stable coronary
artery disease or ACS.18 A post hoc analysis of the Dual
Antiplatelet Therapy Study also identified multiple factors
predicting late ischemic events, including MI at time of PCI
and use of smaller-diameter stents, similar to the current
study. However, the ability of these factors to predict late
ischemic events 12 to 30 months after PCI remained limited
with a c-statistic of 0.64 within a validation cohort.19 Elevated
serum fibrinogen was not measured in these previous studies
and has been identified by the current study to be a unique
independent predictor of MACE up to 2 years after PCI.
Furthermore, the current study highlights how elevated
fibrinogen level augments the association of ACS presenta-
tion, longer total stent length, and small-diameter stent with
2-year MACE. Integrating serum fibrinogen level may help
improve the performance of this late ischemia prediction
model as well. If validated, serum fibrinogen could play a role
in determining which patients could benefit from prolonged
dual-antiplatelet therapy extended beyond 12 months after
index PCI or potentially direct thrombin inhibitors.
Multiple mechanisms may explain the association between
elevated fibrinogen level and long-term cardiovascular events
in the current study population. Serum fibrinogen has a clear
role in arterial thrombosis as a key component of platelet
crosslinking and clot formation.4 Serum fibrinogen is pro-
duced and released in response to systemic inflammation,
which can be present in those with more extensive cardio-
vascular risk factors and coronary heart disease, and further
Figure 1. Factors associated with 2-year MACE after PCI. Adjusted odds ratios for 2-y MACE in the
presence of associated factors during baseline PCI. ACS indicates acute coronary syndrome; CI, confidence
interval; MACE, major adverse cardiovascular events; PCI, percutaneous coronary intervention.
Figure 2. Elevated fibrinogen and 2-y MACE-free survival after
PCI. Kaplan–Meier curves showing decreased 2-y MACE-free
survival in the presence of fibrinogen level ≥280 mg/dL before
and after 24-h landmark analysis (inset). MACE indicates major
adverse cardiovascular events; PCI, percutaneous coronary inter-
vention.
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manifested by acute clinical presentations. Platelet activation
in these contexts can further contribute to release of
intracellular fibrinogen stores, potentiate thrombus formation,
and increase cardiovascular risk. The interplay between these
mechanisms suggests a correlation between elevated fibrino-
gen level and increased cardiovascular events, but a direct
causal link has not been established. Results of the current
study showed that while elevated baseline fibrinogen level
(≥280 mg/dL) is independently associated with 2-year MACE,
it remains a nonspecific marker of events based on receiver-
operator characteristic curve analysis (81.5% sensitivity,
39.0% specificity). We have previously reported that a higher
fibrinogen level (≥345 mg/dL) was associated with peripro-
cedural MI after PCI but also had limited specificity.1 It is
possible that a higher fibrinogen threshold predicts ischemic
risk during PCI with administration of potent antiplatelet/
anticoagulant therapy while a lower threshold might be
associated with longer-term MACE. Furthermore, these iden-
tified cutoffs are within the normal range of the fibrinogen
assay (150–400 mg/dL) and call into question whether a
different range of normal values needs to be ascertained to
better discriminate risk for patients with cardiovascular
Figure 3. Elevated fibrinogen and 2-y MACE-free survival after PCI stratified by significant covariates. Bar graphs showing increased 2-y MACE
in the presence of fibrinogen level ≥280 mg/dL, independent of other significant covariates. ACS indicates acute coronary syndrome; MACE,
major adverse cardiovascular events; PCI, percutaneous coronary intervention.
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disease or those undergoing PCI. A better understanding of
other fibrinogen characteristics such as concentration varia-
tion with time or clinical contexts, isoform variability,
posttranslational modifications, intracellular storage and
release, and binding characteristics may further refine the
relations between an elevated fibrinogen level and 2-year
MACE after PCI.
Similar to the GRAVITAS Trial, results of the current study did
not showasignificant relationshipbetweenmeasuresof platelet
reactivity using the VerifyNow P2Y12 assay (including PRU and
percent platelet inhibition values) and occurrence of MACE. The
current study was specifically powered to detect a difference in
fibrinogen level across outcome groups and may have been
underpowered to also detect differences in platelet function
measurements. Nevertheless, study results show that baseline
fibrinogen level was more closely associated than platelet
function with the occurrence of MACE at 2 years after PCI.
Limitations
This was a retrospective study and findings should be confirmed
in a prospective manner. Post-PCI dual antiplatelet therapy and
thienopyridine selection was determined at time of discharge
after index procedure and may have been subsequently
modified. Fibrinogen level was obtained at a single time point
and variability in its level over time was not assessed. Platelet
function test results were not available for all study subjects.
Conclusions
Elevated serum fibrinogen level (≥280 mg/dL) is indepen-
dently associated with 2-year MACE after PCI, driven by
objective, clinically relevant ischemic events. ACS indication
for initial PCI, TSL ≥32 mm, use of stents ≤2.5 mm, and any
BMS use during PCI are also independent predictors of 2-year
MACE. The highest 2-year MACE is predicted by the presence
of these factors together, while measures of on-thienopyridine
platelet reactivity using the VerifyNow P2Y12 assay are not
associated with 2-year MACE after PCI.
Figure 4. Elevated fibrinogen and 2-y MACE after PCI (24-h landmark analysis). Landmark analysis at
24 h (excluding biomarker-positive periprocedural MI after PCI) showing increased total MACE, and
individual components of MACE, occurring between 24 h and 2 y after PCI in those with fibrinogen
≥280 mg/dL. MACE indicates major adverse cardiac events; MI, myocardial infarction; NSTEMI, non–ST-
segment–elevation myocardial infarction; PCI, percutaneous coronary intervention; TIA, transient ischemic
attack.
Figure 5. Kaplan–Meier curves show a stepwise increase in 2-y
MACE (8.3% vs 18.6% vs 31.2%, vs 54.9% vs 84.6%, log-rank
P<0.001) in the presence of none (blue) or any combination of 1
(green), 2 (orange), 3 (red), or 4 (purple) previously identified risk
factors: ACS indication for PCI, fibrinogen ≥280 mg/dL, use of a
bare-metal stent, use of a ≤2.5-mm diameter stent, and total
stent length ≥32 mm. No subject had all 5 risk factors. ACS
indicates acute coronary syndrome; MACE, major adverse
cardiovascular events; PCI, percutaneous coronary intervention.
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